Title: Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis
Associated condition: Ulcerative colitis
Status: Currently enrolling
Brief summary: Phase 2, multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the safety, tolerability, efficacy and dose-response of GSK2831781 in subjects who have moderate to severe active ulcerative colitis.
Subjects will be randomized to receive GSK2831781 intravenous (IV) infusion, GSK2831781 subcutaneous (SC) injection, placebo IV infusion, or placebo SC injection.
Primary objectives: To assess the safety, tolerability, efficacy and dose-response of GSK2831781 as compared with placebo.
Estimated length of study: The Estimated Study Completion Date is May 17, 2023.
For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.
